Frederick. R. Rickles

Frederick. R. Rickles's AcademicInfluence.com Rankings

Philosophy

#9207

World Rank

#12731

Historical Rank

Logic

#6197

World Rank

#7687

Historical Rank

philosophy Degrees

Frederick. R. Rickles

Biology

#12609

World Rank

#16096

Historical Rank

Biochemistry

#2165

World Rank

#2310

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Frederick. R. Rickles Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Frederick. R. Rickles's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. (2003) (2222)
Activation of blood coagulation in cancer: Trousseau's syndrome revisited. (1983) (765)
In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease (1996) (581)
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. (2005) (475)
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. (1973) (424)
Tissue factor, thrombin, and cancer. (2003) (388)
Molecular basis for the relationship between thrombosis and cancer. (2001) (348)
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. (2004) (345)
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. (1999) (343)
Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 (1984) (332)
Pathophysiology of the thrombophilic state in the cancer patient. (1999) (278)
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. (1998) (275)
Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. (1981) (215)
Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. (1981) (208)
Epidemiology of Thrombosis in Cancer (2001) (194)
Mechanisms of Cancer-Induced Thrombosis in Cancer (2006) (182)
Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. (1985) (161)
Abnormalities of blood coagulation tests in patients with cancer. (1987) (155)
Abnormalities of blood coagulation in patients with cancer: Fibrinopeptide a generation and tumor growth (1983) (150)
Hemostatic alterations in cancer patients. (1992) (144)
Effects of all‐trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia (2004) (130)
The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer (2001) (129)
The role of human T cells (and T cell products) for monocyte tissue factor generation. (1980) (127)
Hemostatic alterations in cancer patients (2005) (123)
Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. (1987) (118)
Delayed hypersensitivity in man: effects of systemic anticoagulation. (1978) (113)
Tissue factor and fibrin in tumor angiogenesis. (2004) (113)
Tissue factor generation by human mononuclear cells: effects of endotoxin and dissociation of tissue factor generation from mitogenic response. (1977) (110)
Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A. (1973) (107)
Rationale and experimental design for the va cooperative study of anticoagulation (warfarin) in the treatment of cancer (1979) (105)
Thrombosis associated with angiogenesis inhibitors. (2009) (104)
Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. (1981) (99)
Mononuclear cell tissue factor: cell of origin and requirements for activation (1979) (97)
Tissue factor and cancer. (2008) (88)
Mononuclear cell tissue factor: cell of origin and requirements for activation. (1979) (86)
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status (1993) (84)
Tissue factor and angiogenesis in cancer (2002) (82)
Venous Thromboembolism in Malignancy and Malignancy in Venous Thromboembolism (1998) (81)
Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? (2007) (78)
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. (2003) (77)
Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin (2002) (77)
Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. (1985) (74)
A new variant of hereditary hemolytic anemia with stomatocytosis and erythrocyte cation abnormality. (1971) (72)
IMMUNOHISTOLOGICAL ANALYSIS OF SERIAL BIOPSIES TAKEN DURING HUMAN RENAL ALLOGRAFT REJECTION: CHANGING PROFILE OF INFILTRATING CELLS AND ACTIVATION OF THE COAGULATION SYSTEM (1985) (71)
Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. (1990) (70)
Endotoxin-induced degranulation of the Limulus amebocyte. (1982) (70)
Guidelines for Clotting Studies in Cancer Patients (1993) (69)
Human Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis (1990) (69)
New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. (1993) (68)
The effects of epinephrine infusion in patients with von Willebrand's disease. (1976) (66)
Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies. (2007) (65)
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon (1992) (64)
The use of continuous infusion of factor concentrates in the treatment of hemophilia (1989) (63)
Tissue factor apoprotein: intracellular transport and expression in shed membrane vesicles. (1987) (62)
Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. (2008) (62)
Hemostatic complications of angiogenesis inhibitors in cancer patients (2008) (62)
Tissue factor expression in human leukemic cells. (1996) (61)
The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor (1992) (59)
Structural features of Salmonella typhimurium lipopolysaccharide required for activation of tissue factor in human mononuclear cells. (1977) (59)
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. (2013) (59)
von Willebrand's disease and hemorrhagic telangiectasia: association of two complex disorders of hemostasis resulting in life-threatening hemorrhage. (1977) (58)
Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. (1988) (57)
Macrophage procoagulants. (1984) (56)
Role of coagulation system in pathophysiology of sickle cell disease. (1974) (55)
Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin. (1987) (55)
Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. (2005) (54)
Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients. (1988) (53)
Molecular mechanisms linking thrombosis and angiogenesis in cancer. (1997) (53)
Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. (1988) (53)
Severe hyponatremia after repeated intravenous administration of desmopressin (1989) (50)
Functional features of lymphocytes recovered from a human renal allograft. (1973) (50)
Activation of blood coagulation in Crohn's disease (1987) (49)
Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. (2014) (46)
Activation of clotting factors in cancer. (2009) (42)
The role of leukocytes in the activation of blood coagulation. (1992) (41)
The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. (1994) (41)
The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481—The Home INR Study (THINRS) (2005) (40)
Fibrin induction of tissue factor expression in human vascular endothelial cells. (1997) (39)
Platelets and malignancy Rationale and experimental design for the VA Cooperative Study of RA‐233 in the treatment of cancer (1982) (39)
In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. (1994) (39)
Long-term follow-up of antibiotic-treated tropical sprue. (1972) (37)
Pregnancy management and successful outcome of Ehlers-Danlos syndrome type IV. (1987) (36)
The Limulus Blood Cell Secretes α2-Macroglobulin When Activated. (1990) (35)
Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Awareness and Prophylaxis Practices Reported by Patients with Cancer (2015) (34)
Continuous infusion of monoclonal antibody‐purified factor VIII (1991) (33)
Eosinophilic leukemoid reaction. Report of a case, its relationship to eosinophilic leukemia, and review of the pediatric literature. (1972) (33)
Evidence for Enhanced Tissue Factor Expression in Age-related Macular Degeneration (2010) (31)
Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring (1999) (30)
Acute hepatic vein thrombosis occurring during therapy for hodgkin's disease. A case report (1979) (30)
Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism. (2011) (28)
Production of modified crosslinked cell‐free hemoglobin for human use: the role of quantitative determination of endotoxin contamination (1993) (28)
Capture of Lipopolysaccharide (Endotoxin) by the Blood Clot: A Comparative Study (2013) (28)
Markers of thrombotic activity in arterial disease. (1987) (25)
Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors. (1993) (25)
Thrombotic Thrombocytopenic Purpura in Pregnancy: Successful Treatment with Plasma Exchange (1995) (25)
Accrual of patients into a multihospital cancer clinical trial and its implications on planning future studies (1981) (24)
Recurrent acute hepatitis following the use of factor VIII concentrates. (1980) (23)
Expression of procoagulant activity in a human monocyte-like cell line. (1983) (23)
Production and characterization of a monoclonal antibody (A1-3) that binds selectively to activated monocytes and inhibits monocyte procoagulant activity. (1986) (23)
Functional interaction of concanavalin A and bacterial endotoxin (lipopolysaccharide): effects on the measurement of endogenous pyrogen release, human mononuclear cell tissue factor activation, lymphocyte DNA synthesis, and gelation of Limulus amebocyte lysate. (1979) (22)
Research Priorities in Hereditary Hemochromatosis (1998) (21)
Chloral hydrate and warfarin interaction: clinical significance. (1971) (20)
A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism (2012) (19)
Mononuclear cell modulation of fibroblast procoagulant activity. (1982) (17)
A Randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). (2002) (17)
Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of veterans affairs cooperative study 188 (1995) (17)
Asymptomatic factor VII deficiency: gene analysis and structure–function relationships (2010) (16)
Immunohistological studies with A1-3, a monoclonal antibody to activated human monocytes and macrophages. (1986) (16)
Preliminary characterization of the procoagulant material in human ascites. (1987) (16)
Purification and preliminary characterization of rabbit vitamin K-dependent coagulation proteins. (1990) (15)
Studies of Cross-Reactivity of Acquired Factor VIII Inhibitor Activity in Hemophilic Plasma (1967) (13)
Relationship of blood clotting and tumor angiogenesis. (2001) (13)
Mechanisms of cancer-induced thrombosis (2006) (13)
Treatment of venous thromboembolism in cancer patients. (1998) (12)
Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin. (1979) (12)
Chloral hydrate and warfarin therapy. (1971) (12)
Cancer and thrombosis in women - molecular mechanisms. (2009) (12)
Fibrinopeptide A during normal pregnancy. (1988) (11)
If heparanase is the answer, what is the question? (2006) (10)
Aspirin insensitive thrombophilia: transcript profiling of blood identifies platelet abnormalities and HLA restriction. (2013) (9)
Nε(γ-glutamyl)lysine crosslinks in the blood clot of the horseshoe crab, Limulus polyphemus (1992) (9)
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE) (2003) (9)
Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy. (1993) (8)
Antimetastatic agents. II. Summary of the interactions of tumor cells with blood coagulation factors, platelets, fibrinolytic factors, and inflammatory cells and their soluble mediators: potential for therapeutic interventions. (1988) (8)
On the origin of leukocyte procoagulant activity. (1978) (8)
Impaired mononuclear cell tissue factor generation in patients with immunodeficiency diseases. (1980) (8)
Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer. (2016) (7)
Tumor angiogenesis and blood coagulation (2004) (7)
Thrombosis and lung cancer. (1989) (7)
Oral and Poster Presentations (2003) (7)
Targeting the Endothelium in Cancer – The Importance of the Interaction of Hemostatic Mechanisms and the Vascular Wall for Tumor Growth and Angiogenesis (2003) (7)
Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. (1995) (7)
Inhibition of rat skin allograft rejection by cyclosporine. In situ characterization of the impaired local immune response. (1986) (7)
Treatment of Venous Thromboembolism in Cancer Patients (1998) (5)
Macrophage Procoagulants, Fibrin Deposition, and the Inflammatory Response (1986) (5)
Reemergence of the International Normalized Ratio for the standardization of prothrombin time. (1993) (5)
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No (2005) (5)
Procoagulant and platelet aggregating properties of antilymphocyte sera. (1976) (5)
Comparison of local versus central tumor measurements in a multicenter cancer trial (1981) (4)
Coagulation abnormalities in cancer patients. Clinical relevance. (1994) (4)
Coexistence of a primary immunodeficiency disorder and hodgkin's disease: Evidence against a B‐Lymphocyte origin for the reed‐sternberg cell (1981) (4)
The infrequent removal of retrievable IVC filters. (2013) (3)
Thermal injury in von willebrand disease. Management of burn wound bleeding. (1976) (3)
Surveillance for hemophilia and inherited hematologic disorders (2000) (3)
The potential pathophysiological role of tissue factor in age-related macular degeneration (2010) (3)
Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: leukemic cell procoagulant activity is not responsible for the hypercoagulable state. (1995) (3)
Thrombolytic (fibrinolytic) drugs and progress in treating cardiovascular disease 1 (2005) (3)
Influence of age, performance status, body weight, and tumor type in individuals with cancer on the disposition of warfarin and its enantiomers: Department of Veterans Affairs cooperative study number 75. (1992) (2)
Reply to “Tissue factor expression in normal and abnormal mammary gland” (1996) (2)
CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV. (2015) (2)
Chloral hydrate and warfarin. (1972) (2)
Global public awareness of venous thromboembolism: comment (2016) (2)
Immunohistologic profile of cells infiltrating acutely rejecting and long-surviving rat cardiac allografts. (1988) (2)
Cancer and thrombosis is a sticky business. (2008) (2)
2 birds with 1 stone (2008) (2)
Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report (1993) (2)
Endotoxin contamination of biological reagents: detection and removal of endotoxin with Limulus amebocyte lysate. (1979) (1)
SEVERE COMBINED IMMUNODEFICIENCY DISEASE: A DISORDER OF BOTH IMMUNE FUNCTION AND BLOOD COAGULATION (1979) (1)
Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma (2013) (1)
Enhancing participation in clinical research: keys to obtaining informed consent. (2007) (1)
Monocyte pro coagulant activity recognition by mono clonal anti tissue factor antibody and evidence for in vivo regulation (1983) (1)
OT-304, a novel, anti-angiogenesis agent with multiple inhibitory effects on proliferation, angiogenesis, and tumor progression (2008) (1)
N epsilon(gamma-glutamyl)lysine crosslinks in the blood clot of the horseshoe crab, Limulus polyphemus. (1992) (1)
Functional heterogeneity of human splenic lymphocytes (1973) (1)
Binding studies of radioactive lipopolysaccharide with Limulus amebocytes. (1979) (1)
A joint practice appraoch to the care of persons with cancer. (1980) (1)
Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and prophylaxis practices reported by patients with cancer. (2011) (1)
Thrombosis and Bleeding Complications in Malignant Hematologic Disorders (2007) (1)
Modulation of Cancer Cell-Associated Procoagulant Activity (PCA) by a Novel, Small Molecule, Orally Active Inhibitor of Oxidative Stress Pathways (2008) (1)
6th International Conference on Thrombosis and Hemostasis Issues in Cancer. Preface. (2012) (0)
Recurrent Acute Hepatitis Following the Use of Antihemophilic Factor Concentrates (1977) (0)
Author and Subject Index (2001) (0)
CleavageofBloodCoagulation FactorXIII andFibrinogen byThrombinduringInVitro Clotting (1985) (0)
Thrombosis and Haemostasis Issues in Cancer: 2nd International Conference, Bergamo, September 2003: Lectures and Abstracts (2003) (0)
Is tissue factor the ‘original sin’ of clotting, or is it factor VII? (2007) (0)
Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa, Italy, April 23-25, 2010. Preface. (2010) (0)
Deep Vein Thrombosis and Pulmonary Embolism: Awareness and Knowledge Gaps In the General Public and at-Risk Oncology Patients (2010) (0)
Panel discussion on the treatment of inhibitors: Today and tomorrow (1995) (0)
Improving Radiology Procedure Identification for Inferior Vena Cava (IVC) Filters using EHR Text (2015) (0)
THE DISTRIBUTION OF CROSS-LINKED FIBRIN IN HUMAN LUNG CARCINOMA PARALLELS THAT OF ACTIVATED HOST MONONUCLEAR LEUKOCYTES: IMMUNO-HISTOLOGIC STUDIES WITH MONOCLONAL ANTIBODIES (1987) (0)
Increased Tissue Factor Expression in ARPE19 Cells After Lipopolysaccharide and Hydrogen Peroxide Treatment (2010) (0)
Effects of endotoxin on human lymphocytes (1973) (0)
Acquired antithrombin III deficiency—rationale for replacement therapy. Introduction and overview—What are the questions? (1994) (0)
Pharmacologic Thromboprophylaxis Is Frequently Prescribed In Hospitalized Cancer Patients At Academic Medical Centers: A Prospective, Cross-Sectional, Multi-Center Study (2013) (0)
Frederick R. Rickles, MD, FACP, Appointed Executive Director of the Federation of American Societies for Experimental Biology (2004) (0)
Role of Procoagulant Activity in Neoplastic Disease (2019) (0)
The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting. (2016) (0)
CHAPrER 22. HEMOSTATIC ALTERATIONS IN CAIlCER PATIER'l'S (1984) (0)
Hemostatic changes in canger (1992) (0)
Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study (2018) (0)
utilization of elastic compression stockings (ecs) following first episode of deep venous thrombosis (dvt): 15 year experience at a single veterans affairs medical center (vamc) : Vb05 (2014) (0)
Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
Other Uses of LMWHs – Miscellaneous (1998) (0)
Incidence and risk factors (2004) (0)
Immunohistological studies with a monoclonal antibody to human tissue factor: normal distribution and usefulness as a marker for activated macrophages (1984) (0)
A worldwide survey to assess the current approach to the treatments of cancer and venous thromboembolism (2013) (0)
Research Abstracts: 12th National Conference on Anticoagulant Therapy (2013) (0)
Chapter 23 – Thrombosis and Cancer (2007) (0)
Antimalignant properties of antithrombotic agents (2004) (0)
immunoassay for TIA would make this a more real- istic goal for application to larger clinical trials. (2017) (0)
7th international conference on thrombosis and hemostasis issues in cancer. Preface. (2014) (0)
A worldwide survey to assess the treatment approach of cancer associated venous thromboembolism (CAT) (2013) (0)
The Expression of Tissue Factor in Eyes With Age-Related Macular Degeneration (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Frederick. R. Rickles?

Frederick. R. Rickles is affiliated with the following schools:

Frederick. R. Rickles's Academic­Influence.com Rankings

Why Is Frederick. R. Rickles Influential?

Frederick. R. Rickles's Published Works

Published Works

What Schools Are Affiliated With Frederick. R. Rickles?

Frederick. R. Rickles's AcademicInfluence.com Rankings